Switch theme
Sign up to access all valuation multiples
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
1994
390
Last FY Revenue $239M
Last FY EBITDA -$51.3M
$123M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Intercure achieved revenue of $239M and an EBITDA of -$51.3M.
Intercure expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Intercure valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $239M | XXX | XXX | XXX |
| Gross Profit | XXX | $30.2M | XXX | XXX | XXX |
| Gross Margin | XXX | 13% | XXX | XXX | XXX |
| EBITDA | XXX | -$51.3M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -21% | XXX | XXX | XXX |
| EBIT | XXX | -$45.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -19% | XXX | XXX | XXX |
| Net Profit | XXX | -$67.8M | XXX | XXX | XXX |
| Net Margin | XXX | -28% | XXX | XXX | XXX |
| Net Debt | XXX | $105M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Intercure's stock price is $2.
Intercure has current market cap of $85.4M, and EV of $123M.
See Intercure trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $123M | $85.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Intercure has market cap of $85.4M and EV of $123M.
Intercure's trades at 0.5x EV/Revenue multiple, and -2.4x EV/EBITDA.
Equity research analysts estimate Intercure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Intercure's P/E ratio is not available.
See valuation multiples for Intercure and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $85.4M | XXX | $85.4M | XXX | XXX | XXX |
| EV (current) | $123M | XXX | $123M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -2.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -1.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIntercure's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.2M for the same period.
Intercure's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Intercure's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Intercure and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -21% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Intercure acquired XXX companies to date.
Last acquisition by Intercure was XXXXXXXX, XXXXX XXXXX XXXXXX . Intercure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Intercure founded? | Intercure was founded in 1994. |
| Where is Intercure headquartered? | Intercure is headquartered in United States of America. |
| How many employees does Intercure have? | As of today, Intercure has 390 employees. |
| Who is the CEO of Intercure? | Intercure's CEO is Mr. Alexander Rabinovich. |
| Is Intercure publicy listed? | Yes, Intercure is a public company listed on NAS. |
| What is the stock symbol of Intercure? | Intercure trades under INCR ticker. |
| When did Intercure go public? | Intercure went public in 2019. |
| Who are competitors of Intercure? | Similar companies to Intercure include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Intercure? | Intercure's current market cap is $85.4M |
| Is Intercure profitable? | Yes, Intercure is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
